Search

You searched for "registrars"

483 results found

Abiraterone acetate in men with castration-resistant prostate cancer

1 November 2017 | | URO - Urologic Oncology
With emerging results from the Stampede and Latitude studies, abiraterone has taken the forefront in the management of metastatic prostate cancer while researchers try to identify the ideal timing for administration. It is a potent inhibitor of CYP17 which results...

Radium-223 treatment outcomes after multiple lines of mCRPC therapy in clinical practice: implication of pre-treatment spinal epidural disease

1 September 2017 | | URO - Urologic Oncology
There are a number of treatments now available to patients with metastatic castrate-resistant prostate cancer (mCRPC). However, the optimal timing and order in which they are given is less clear. Radium-223 was FDA-approved for mCRPC patients with symptomatic bone metastases...

Predicting bone scan positivity in non-metastatic CRPC

1 May 2016 | | URO - Urologic Oncology
There is evidence that suggests that early treatment with chemotherapy, immunotherapy or hormone therapy leads to a better response in patients with asymptomatic metastatic castrate resistant prostate cancer (CRPC). This study aimed to predict bone scan positivity in patients with...

The potential of statin use in castrate resistant prostate cancer treatment

1 May 2016 | | URO - Urologic Oncology
One of the mechanisms by which prostate cancer achieves castrate resistance is through de novo intratumoral production of androgens. Reactivation of androgen receptors results in promotion of cell survival and proliferation pathways despite castrate serum testosterone levels. As androgen synthesis...

PREDICT Prostate – individualised, evidence-based estimates of survival and treatment benefit

5 November 2019 | | URO - Urologic Oncology, URO - Technology
Earlier this year ‘PREDICT Prostate’ was launched online alongside a high-profile publication in PLOS Medicine. The prognostic model and decision-aid has been designed to inform treatment decision-making among men newly diagnosed with non-metastatic prostate cancer. David Thurtle and Vincent Gnanapragasam...

FLOW-CLEAN - Flushable Uroflow Toilet

5 September 2019 | Research & Development
Ease of use and proven effectiveness Hygienic and cost saving solution for flowmetry

The conservative assessment and treatment of mixed urinary and anal incontinence in women: a multidisciplinary approach

1 September 2019 | | URO - Functional / Reconstructive Urology, URO - Neurourology
Mixed urinary incontinence Urinary incontinence (UI) is considered to be a highly prevalent condition; however, depending upon the definitions used, actual reported prevalence rates can vary significantly. The International Consultation on Incontinence (ICI) review [1], reported unadjusted prevalence estimates for...

How to set up and run a cadaveric dissection course

1 January 2018 | | URO - Core Urology
Conducting and implementing a cadaveric dissection course requires careful planning. Rachel Edmiston, Rajesh Anmolsingh, Omar Mirza and Nirmal Kumar offer a guide to individuals highlighting the licensing and legal processes involved with the use, preservation and disposal of cadavers in...

‘No Deal’ Brexit – how might it impact urological practice in the UK?

1 September 2018 |
On 29 March 2017, the Government of the United Kingdom of Great Britain & Northern Ireland triggered Article 50 of the Lisbon Treaty, formally starting the two-year period for talks with the European Union (EU) in which to reach a...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

1 May 2017 | | URO - Urologic Oncology
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

Focal therapy trials

6 November 2020 | | URO - Urologic Oncology
Men with localised prostate cancer have traditionally required whole gland treatment involving radical prostatectomy or radical radiation treatment, independent of disease location and size. Increasing evidence supports the use of active treatment only in those men diagnosed with prostate cancer...

International urology returns to Scotland

31 March 2025 | URO - Core Urology
Founded in 1907, the SIU has established itself as the premier international professional society for urologists. As global interdependence increases, so does the relevance of the Society’s mission to enable urologists in all nations to apply the highest standards of...